ActiGraph's Response to Novel Coronavirus (COVID-19) - March 24th Update
- Home /
- COVID-19 Response
ActiGraph COVID-19 Update – March 24, 2020
Dear Valued Customer,
We realize that you depend on ActiGraph’s products and solutions for your active and upcoming clinical trials and research studies. We also realize that delays on our end could impact your timelines significantly. As we navigate the COVID-19 pandemic together, we are committed to communicating any potential roadblocks that may impact your work.
We want to assure you that ActiGraph is working closely with our clients and supply chain partners so we can continue to deliver the products and services you need during these unprecedented times.
Our operations are up and running with many employees working from home. Our teams are equipped with the technology and tools they need to continue to serve you during our regular business hours. Many of our pharmaceutical clients are hosting virtual meetings, and our account managers have been attending and contributing. We do not anticipate delays in responding to service requests.
As of Tuesday, March 24, 2020, our hardware manufacturers have no plans to halt or decrease production. Our parts suppliers are flush with stock, and our plastic housing manufacturers have indicated they will be able to keep up with expected demands.
Despite the hardships we are all experiencing during this time, we feel encouraged that we’re on the right path. The ability to capture and deliver remote patient data is in our DNA, and our mission has taken on a new sense of urgency in the face of this global pandemic. We see a promising future in clinical trials and academic studies, and we will continue to press forward to fulfill our mission of helping people live better, longer lives through innovative collaborations with partners like you.
If you have any questions or concerns, please reach out to our Support Team. We’re happy to help in any way that we can.
ActiGraph Response to Novel Coronavirus (COVID-19)
In response to the global novel coronavirus (COVID-19) pandemic, ActiGraph is actively monitoring external factors that could impact our ability to fulfill orders and meet our customers’ needs. We have enacted procedures to ensure the safe handling of outgoing materials and minimize disruption to active and upcoming studies. In addition, we have policies, procedures, and tools in place to ensure that our teams are able to work remotely to support business operations should the need arise. We will continue to monitor this evolving situation and update this statement as needed.
All inbound shipping boxes are sanitized with Lysol® disinfectant upon arrival and again before they are opened. All components and products received are sanitized with alcohol prep pads and handled with sterile latex-free gloves.
We are not currently experiencing any inventory supply chain delays. In preparation for any forthcoming delays, we have identified additional materials suppliers and ordered a surplus of inventory items to minimize order fulfillment disruption.
There are currently no widespread shipment delays with the exception of regions of China and Italy. We will continue to monitor FedEx service alerts and update this statement if further alerts are issued.
Staff and Travel
All business travel has been cancelled through April 15th, 2020. In the event that our facility is temporarily closed, ActiGraph personnel will work remotely to ensure that client and business needs are met. This will help ensure that site activations and patient enrollments can continue as scheduled for our pharmaceutical clients.